瑞舒伐他汀与阿托伐他汀在日本合并糖尿病的高胆固醇血症患者中降脂作用及对糖代谢影响的差异。强效他汀类药物在2型糖尿病高脂血症患者中的降脂作用（LISTEN）研究。
Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes. Lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabetes patients (LISTEN) study –.
作者信息
Ogawa Hisao, Matsui Kunihiko, Saito Yoshihiko, Sugiyama Seigo, Jinnouchi Hideaki, Sugawara Masahiro, Masuda Izuru, Mori Hisao, Waki Masako, Yoshiyama Minoru, Watada Hirotaka
机构信息
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University.
出版信息
Circ J. 2014;78(10):2512-5. doi: 10.1253/circj.cj-14-0810. Epub 2014 Sep 2.
BACKGROUND
Little is known about the differences between standard-dose statins effects on glucose level and lipids in Japanese patients with diabetes mellitus (DM).
METHODS AND RESULTS
The 1,049 patients were randomly assigned to either the rosuvastatin group or atorvastatin group. There were no significant differences between the 2 groups in the effect on non-high-density lipoprotein cholesterol (non-HDL-C) and HbA1c at 12 months. However, physicians tended to switch to more intensive therapy for DM in the atorvastatin group.
CONCLUSIONS
Rosuvastatin 5 mg and atorvastatin 10 mg have a similar lowering effect on non-HDL-C, but might be different in terms of adverse effect on glucose levels.
背景
关于标准剂量他汀类药物对日本糖尿病患者血糖水平和血脂影响的差异，目前所知甚少。
方法与结果
1049例患者被随机分为瑞舒伐他汀组或阿托伐他汀组。两组在12个月时对非高密度脂蛋白胆固醇（non-HDL-C）和糖化血红蛋白（HbA1c）的影响无显著差异。然而，阿托伐他汀组的医生倾向于对糖尿病采用更强化的治疗。
结论
5毫克瑞舒伐他汀和10毫克阿托伐他汀对非高密度脂蛋白胆固醇有相似的降低作用，但对血糖水平的不良反应可能有所不同。
Zotero 插件